Dashboard 3 · Consultant Strategy Builder

Pharma Corporate Strategy — Board Report

McKinsey-grade transformation strategy across a 30,000-project, $75.6B enterprise — MECE-structured from business diagnosis through BCG / GE-McKinsey portfolio logic to a CEO recommendation.
Senior Partner workbench · MECE · Pyramid Principle · BCG · GE-McKinsey · Board-ready · Generated with Claude Code
01

Executive Summary

Board-ready strategy synthesis — MECE structured, Pyramid-Principle led (governing thought → 3 pillars → evidence)
Book of Business
$75.6B
30,000 projects · 5 clients
Portfolio EBITDA
25.0%
$18.9B absolute
Blended ROI
116%
7% value-destructive
Avg Risk Score
51/100
enterprise risk index
Stars in Portfolio
7,553
25% of revenue
Digital Maturity
3.0/5
40% at/below level 2
Market Growth
10.0%
weighted portfolio
ESG Score
50/100
sustainability index

Governing thought: this $75.6B, 30,000-project enterprise is financially sound but strategically undifferentiated — EBITDA is healthy (25.0%) and growth positive (10.0%), yet value creation is spread thin (7% of projects are value-destructive) and digital maturity (3.0/5) lags. The mandate is concentration: fund the Stars, fix or exit the Dogs, and close the digital gap.

Pillar 1 — Concentrate the portfolio
Stars hold 25% of revenue at 115% ROI; Dogs tie up $18.6B. Reallocate from Dogs to Stars.
Pillar 2 — Restore return discipline
7% of projects have negative ROI. A stage-gated capital process lifts blended ROI toward the Expand cohort's 114%.
Pillar 3 — Close the digital gap
40% of the portfolio sits at digital maturity ≤2. A funded AI/digital program is the single largest cross-cutting margin lever.
CEO ask: approve a portfolio rebalancing that shifts capital from 7,399 Dog projects into Stars and Expand-rated growth, funds an enterprise AI/digital uplift, and installs a 12-KPI operating cadence (§18–22).
02

Current Business Diagnosis

Where the enterprise stands today across financial, portfolio and capability axes
Revenue by client
Biotech XBiotech X: $15.4$15.4Global Pharma BGlobal Pharma B: $15.2$15.2Global Pharma AGlobal Pharma A: $15.1$15.1MedTech YMedTech Y: $14.9$14.9Generic ZGeneric Z: $14.9$14.9
Diagnostic scorecard
DimensionValueRead
EBITDA margin25.0%Healthy
Blended ROI116%Positive but thin
Value-destructive projects7%Fix
Digital maturity3.0/5Lagging
Supply-chain score50/100Mid
ESG score50/100Mid
Enterprise risk51/100Elevated
03

Market Position

Competitive strength and growth posture of the book
Competitive strength by client
Dashed = portfolio average 50/100
574329140Biotech X: 5151Global Pharma B: 5050Global Pharma A: 5050MedTech Y: 5151Generic Z: 5050target 50Biotech XGlobal Pharma BGlobal Pharma AMedTech YGeneric Z
Market growth by client
11.4%8.6%5.7%2.9%0.0%Biotech X: 10.2%10.2%Global Pharma B: 10.1%10.1%Generic Z: 10.0%10.0%MedTech Y: 10.0%10.0%Global Pharma A: 9.9%9.9%Biotech XGlobal Pharma BGeneric ZMedTech YGlobal Pharma A
04

Portfolio Assessment

Distribution of the book across the BCG growth-share archetypes
Revenue by BCG quadrant
Star: 18,866 (25.0%)Cash Cow: 19,250 (25.5%)Question Mark: 18,863 (25.0%)Dog: 18,597 (24.6%)$76Bbook
Star 25%
Cash Cow 25%
Question Mark 25%
Dog 25%
Project count by quadrant
8.5K6.4K4.2K2.1K0Star: 7,5537.6KCash Cow: 7,5667.6KQuestion Mark: 7,4827.5KDog: 7,3997.4KStarCash CowQuestion MarkDog
Portfolio archetype scorecard
QuadrantProjectsRevenue ($B)Rev shareEBITDAROIAction
Star755318.925%24.8%115%Invest
Cash Cow756619.226%25.0%116%Harvest
Question Mark748218.925%25.2%116%Selective
Dog739918.625%25.1%116%Divest
05

BCG Growth–Share Matrix

50 portfolios positioned by competitive strength × market growth, sized by revenue
Portfolio positioning (bubble = revenue, color = archetype)
Question MarksStarsDogsCash CowsPortfolio-1: Star, growth 9.4%, comp 48Portfolio-10: Cash Cow, growth 9.8%, comp 47Portfolio-11: Cash Cow, growth 9.9%, comp 53Portfolio-12: Cash Cow, growth 9.9%, comp 51Portfolio-13: Question Mark, growth 10.7%, comp 52Portfolio-14: Dog, growth 10.0%, comp 53Portfolio-15: Question Mark, growth 10.6%, comp 51Portfolio-16: Question Mark, growth 9.9%, comp 52Portfolio-17: Question Mark, growth 9.9%, comp 50Portfolio-18: Cash Cow, growth 10.5%, comp 49Portfolio-19: Star, growth 10.5%, comp 50Portfolio-2: Star, growth 10.5%, comp 51Portfolio-20: Star, growth 10.2%, comp 50Portfolio-21: Cash Cow, growth 9.6%, comp 50Portfolio-22: Cash Cow, growth 10.0%, comp 50Portfolio-23: Question Mark, growth 10.2%, comp 51Portfolio-24: Cash Cow, growth 9.5%, comp 48Portfolio-25: Cash Cow, growth 10.3%, comp 50Portfolio-26: Dog, growth 10.0%, comp 53Portfolio-27: Cash Cow, growth 9.8%, comp 51Portfolio-28: Dog, growth 9.9%, comp 49Portfolio-29: Dog, growth 9.8%, comp 49Portfolio-3: Question Mark, growth 9.6%, comp 51Portfolio-30: Cash Cow, growth 9.8%, comp 51Portfolio-31: Star, growth 10.3%, comp 53Portfolio-32: Star, growth 9.6%, comp 52Portfolio-33: Dog, growth 9.6%, comp 48Portfolio-34: Cash Cow, growth 10.5%, comp 51Portfolio-35: Cash Cow, growth 10.1%, comp 50Portfolio-36: Question Mark, growth 9.7%, comp 50Portfolio-37: Question Mark, growth 10.4%, comp 48Portfolio-38: Dog, growth 9.9%, comp 52Portfolio-39: Star, growth 10.4%, comp 52Portfolio-4: Cash Cow, growth 9.6%, comp 49Portfolio-40: Dog, growth 10.0%, comp 51Portfolio-41: Cash Cow, growth 9.3%, comp 49Portfolio-42: Star, growth 10.4%, comp 52Portfolio-43: Star, growth 10.0%, comp 52Portfolio-44: Star, growth 10.1%, comp 50Portfolio-45: Question Mark, growth 10.4%, comp 47Portfolio-46: Cash Cow, growth 9.9%, comp 46Portfolio-47: Question Mark, growth 11.1%, comp 50Portfolio-48: Cash Cow, growth 10.2%, comp 50Portfolio-49: Cash Cow, growth 10.1%, comp 50Portfolio-5: Dog, growth 10.5%, comp 51Portfolio-50: Question Mark, growth 9.7%, comp 50Portfolio-6: Star, growth 9.9%, comp 51Portfolio-7: Star, growth 10.6%, comp 50Portfolio-8: Dog, growth 9.8%, comp 50Portfolio-9: Star, growth 10.1%, comp 51Competitive strength →Market growth →
● Star● Cash Cow● Question Mark● Dog
06

GE–McKinsey 9-Box Matrix

Clients scored on market attractiveness × competitive strength (invest / selective / harvest)
Client positioning (bubble = revenue)
SelectiveInvest / GrowHarvest / ExitSelectiveBiotech X: attract 8422, strength 5412, 15.4BBiotecGlobal Pharma B: attract 4640, strength 3423, 15.2BGlobalGlobal Pharma A: attract 3483, strength 8701, 15.1BGlobalMedTech Y: attract 2499, strength 6003, 14.9BMedTecGeneric Z: attract 3754, strength 2756, 14.9BGeneriCompetitive strength →Market attractiveness →
Attractiveness = growth 40% · revenue 25% · ESG 15% · (low) risk 20%. Strength = competitive 50% · EBITDA 25% · digital 25%. Top-right clients earn priority investment; bottom-left are harvest/exit candidates.
07

Financial Analysis

Revenue, margin, and cost structure of the enterprise
Revenue
$75.6B
book of business
EBITDA
$18.9B
25.0% margin
OpEx
$22.5B
operating expense
CapEx
$15.1B
capital expenditure
EBITDA margin by client
28.2%21.2%14.1%7.1%0.0%Biotech X: 24.9%24.9%Global Pharma B: 25.0%25.0%Global Pharma A: 25.2%25.2%MedTech Y: 25.0%25.0%Generic Z: 25.0%25.0%target 25.0%Biotech XGlobal Pharma BGlobal Pharma AMedTech YGeneric Z
Cost structure by client ($B)
OpExCapEx$5.2$3.9$2.6$1.3$0.0OpEx · Biotech X: $4.6CapEx · Biotech X: $3.1Biotech XOpEx · Global Pharma B: $4.5CapEx · Global Pharma B: $3.1Global Pharma BOpEx · Global Pharma A: $4.5CapEx · Global Pharma A: $3.0Global Pharma AOpEx · MedTech Y: $4.5CapEx · MedTech Y: $3.0MedTech YOpEx · Generic Z: $4.4CapEx · Generic Z: $3.0Generic Z
08

ROI Analysis

Return performance by archetype and recommendation
ROI by BCG quadrant
130%97%65%32%0%Star: 115%115%Cash Cow: 116%116%Question Mark: 116%116%Dog: 116%116%StarCash CowQuestion MarkDog
ROI by strategic recommendation
131%98%66%33%0%Divest: 116%116%Maintain: 115%115%Invest: 117%117%Expand: 114%114%DivestMaintainInvestExpand
7% of projects destroy value (ROI < 0). Return discipline — not top-line growth — is the fastest path to margin expansion. Redirect capital toward Expand-rated projects (114% ROI) and away from Divest-rated (116%).
09

Cost Optimization & Operational Excellence

Efficiency levers across the cost base and operations
OpEx-to-revenue by client
Lower is leaner
33.5%25.1%16.7%8.4%0.0%Biotech X: 29.7%29.7%Global Pharma B: 29.9%29.9%Global Pharma A: 29.6%29.6%MedTech Y: 29.8%29.8%Generic Z: 29.7%29.7%Biotech XGlobal Pharma BGlobal Pharma AMedTech YGeneric Z
Operational excellence levers
  • Zero-based OpEx review on the highest OpEx/revenue clients.
  • CapEx stage-gating tied to ROI thresholds.
  • Shared-service consolidation across the 5 client units.
  • Procurement synergy from portfolio scale.
10

Growth Strategy & Strategic Options

MECE set of growth pathways ranked by value and feasibility
Strategic options — Ansoff-mapped
OptionThrustEvidencePriority
Concentrate on StarsMarket penetrationStars ROI 115% vs book 116%P1
Expand high-growth QMsProduct/market devQuestion Marks grow 10.1%P2
Geographic expansionMarket developmentUnder-served regions in bookP2
Divest Dogs, redeployPortfolio pruning$18.6B freedP1
Bolt-on M&A in growth TAsInorganicFund from Dog divestitureP3
11

Risk Assessment

Enterprise risk distribution and its link to strategic posture
Risk band distribution
11.5K8.6K5.7K2.9K0Low (<33): 9,8339.8KMedium (33-66): 9,9339.9KHigh (≥66): 10,23410.2KLow (<33)Medium (33-66)High (≥66)
Avg risk by recommendation
Do Divest-rated projects also carry the most risk?
574329140Divest: 5050Maintain: 5151Invest: 5050Expand: 5151DivestMaintainInvestExpand
12

Investment Prioritization & Resource Allocation

Portfolios on a return-vs-risk grid; capital follows the top-right
Return vs. (inverse) risk — 50 portfolios
1100011111Fix or exitFund aggressivelyAvoidSteady / monitorPortfolio-1: ROI 113%, risk 50Portfolio-10: ROI 116%, risk 50Portfolio-11: ROI 108%, risk 52Portfolio-12: ROI 115%, risk 50Portfolio-13: ROI 119%, risk 48Portfolio-14: ROI 120%, risk 50Portfolio-15: ROI 116%, risk 51Portfolio-16: ROI 118%, risk 49Portfolio-17: ROI 116%, risk 52Portfolio-18: ROI 116%, risk 50Portfolio-19: ROI 117%, risk 52Portfolio-2: ROI 115%, risk 50Portfolio-20: ROI 116%, risk 53Portfolio-21: ROI 117%, risk 50Portfolio-22: ROI 121%, risk 51Portfolio-23: ROI 118%, risk 49Portfolio-24: ROI 116%, risk 51Portfolio-25: ROI 116%, risk 51Portfolio-26: ROI 120%, risk 51Portfolio-27: ROI 111%, risk 50Portfolio-28: ROI 114%, risk 49Portfolio-29: ROI 119%, risk 53Portfolio-3: ROI 120%, risk 49Portfolio-30: ROI 113%, risk 50Portfolio-31: ROI 118%, risk 50Portfolio-32: ROI 120%, risk 52Portfolio-33: ROI 114%, risk 49Portfolio-34: ROI 119%, risk 51Portfolio-35: ROI 117%, risk 50Portfolio-36: ROI 114%, risk 50Portfolio-37: ROI 111%, risk 52Portfolio-38: ROI 114%, risk 50Portfolio-39: ROI 112%, risk 51Portfolio-4: ROI 109%, risk 51Portfolio-40: ROI 115%, risk 48Portfolio-41: ROI 114%, risk 49Portfolio-42: ROI 116%, risk 49Portfolio-43: ROI 116%, risk 50Portfolio-44: ROI 119%, risk 51Portfolio-45: ROI 115%, risk 52Portfolio-46: ROI 114%, risk 54Portfolio-47: ROI 117%, risk 51Portfolio-48: ROI 118%, risk 50Portfolio-49: ROI 109%, risk 51Portfolio-5: ROI 114%, risk 51Portfolio-50: ROI 112%, risk 52Portfolio-6: ROI 112%, risk 52Portfolio-7: ROI 110%, risk 51Portfolio-8: ROI 120%, risk 50Portfolio-9: ROI 116%, risk 51Relative ROI →Risk-adjusted safety →
Resource allocation by owner
OwnerProjectsRevenue ($B)Avg ROI
CEO744918.6114%
CFO740418.7118%
CMO756419.1115%
CSO758319.1116%
Capital allocation should follow ROI-adjusted-for-risk, not headcount or historical share.
13

Scenario Planning

Three-year revenue envelope under growth scenarios
Revenue scenarios 2026–2028 ($B)
Upside (+4pp)BaseDownside (−4pp)$108.1$81.1$54.1$27.0$0.0202620272028Upside (+4pp): $75.6Upside (+4pp): $86.2Upside (+4pp): $98.3Base: $75.6Base: $83.2Base: $91.5Downside (−4pp): $75.6Downside (−4pp): $80.1Downside (−4pp): $85.0
Upside
$98.3B
2028 · +4pp growth
Base
$91.5B
2028 · trend growth
Downside
$85.0B
2028 · −4pp growth
14

M&A Opportunities

Inorganic moves funded by portfolio pruning
Divestiture pool (Dog quadrant)
$18.6B
revenue in 7,399 Dog projects — divest / out-license
  • Screen each Dog for competitor-acquisition risk before divesting.
  • Redeploy proceeds into Star acceleration.
Acquisition thesis (growth QMs)
10.1%
avg growth in Question Mark cohort — bolt-on targets
  • Target sub-scale high-growth assets adjacent to Stars.
  • Discipline: walk-away price at 60% of risk-adjusted NPV.
15

Digital Transformation & AI Adoption

Maturity today and the AI opportunity map
Digital maturity distribution (1–5)
40% of projects at level ≤2
6.9K5.2K3.5K1.7K0L1: 5,9546.0KL2: 5,9275.9KL3: 6,0846.1KL4: 6,1916.2KL5: 5,8445.8KL1L2L3L4L5
AI adoption priorities
  • R&D: AI-assisted target ID & trial design.
  • Commercial: next-best-action & payer analytics.
  • Supply chain: demand forecasting & network optimization.
  • G&A: agentic automation of back-office workflows.
  • Foundations: data platform + governance (ISO 42001 / NIST AI RMF).
Closing the digital gap (40% at maturity ≤2) is the largest cross-functional margin lever in this analysis — it compounds across every client and every quadrant.
16

Supply Chain Review

Resilience and efficiency by region
Supply-chain score by region
EUEU: 5151UnassignedUnassigned: 5050LATAMLATAM: 5050MEAMEA: 5050APACAPAC: 5050
ESG score by client
Dashed = portfolio average 50
574329140Biotech X: 5050Global Pharma B: 5050Global Pharma A: 5050MedTech Y: 5050Generic Z: 5151target 50Biotech XGlobal Pharma BGlobal Pharma AMedTech YGeneric Z
17

Organizational Transformation & Change Management

Operating model and adoption plan
Strategic priority mix
P1: 10,074 (33.6%)P2: 10,009 (33.4%)P3: 9,917 (33.1%)10,074P1 projects
P1 34%
P2 33%
P3 33%
Change-management spine
  • Owner accountability: each quadrant action assigned to a named C-suite owner (CEO/CFO/CMO/CSO).
  • Governance: monthly portfolio review against the 12-KPI cadence (§18).
  • Capability: digital/AI academy to lift maturity.
  • Incentives: tie leadership comp to risk-adjusted ROI, not revenue alone.
18

KPI Framework

Twelve board-level metrics with current baseline and target
Enterprise KPI scorecard
KPIBaselineTargetCadence
Blended ROI116%+15ppQuarterly
Value-destructive projects7%<10%Quarterly
EBITDA margin25.0%+3ppQuarterly
Star revenue share25%≥40%Half-yearly
Digital maturity3.0/5≥3.5Half-yearly
Enterprise risk score51/100<45Quarterly
Supply-chain score50/100≥70Half-yearly
ESG score50/100≥65Annual
OpEx / revenue30%−5ppQuarterly
Dog project count7,399−50%Half-yearly
Implementation cycle19 mo−20%Quarterly
Avg market growth10.0%maintainAnnual
19

Executive Dashboard

At-a-glance board view
Revenue
$75.6B
EBITDA
25%
ROI
116%
Risk
51
/100
Digital
3.0
/5
ESG
50
/100
Recommendation mix
Divest: 7,597 (25.3%)Maintain: 7,504 (25.0%)Invest: 7,500 (25.0%)Expand: 7,399 (24.7%)30Kprojects
Divest 25%
Maintain 25%
Invest 25%
Expand 25%
Revenue by recommendation
$21.5$16.1$10.8$5.4$0.0Divest: $19.2$19.2Maintain: $19.0$19.0Invest: $18.9$18.9Expand: $18.4$18.4DivestMaintainInvestExpand
20

30-60-90 Day Action Plan

Sequenced execution to lock in early wins
First 30 days
  • Stand up the portfolio-review board + 12-KPI baseline.
  • Freeze new capital to Dog-quadrant projects.
  • Name C-suite owners per quadrant action.
Days 31–60
  • Complete divestiture screen on 7,399 Dogs.
  • Launch zero-based OpEx review on highest OpEx/revenue units.
  • Approve AI/digital program charter.
Days 61–90
  • Reallocate freed capital to Stars & Expand-rated projects.
  • Ship first AI use-cases in Commercial & Supply Chain.
  • Report ROI & risk deltas to the board.
21

Three-Year Strategic Roadmap

From stabilization to differentiated growth
Year 1 — Concentrate & clean
  • Divest Dogs; redeploy to Stars.
  • Install ROI stage-gates.
  • AI foundations + first use-cases.
Target: ROI +5pp, value-destructive <20%.
Year 2 — Scale & differentiate
  • Scale AI across R&D, Commercial, Supply Chain.
  • Bolt-on M&A in growth QMs.
  • Digital maturity → 3.0+.
Target: EBITDA +2pp, digital ≥3.
Year 3 — Lead
  • Star revenue share ≥40%.
  • Enterprise risk <45.
  • ESG ≥65; supply-chain ≥70.
Target: blended ROI +15pp vs baseline.
22

CEO Recommendation

The decision, the rationale, and the ask
64Transformation index
Recommendation: APPROVE the concentration-and-digitize strategy

The enterprise is sound but undifferentiated. The value is not in doing more — it is in doing less, better: concentrate capital on Stars, exit Dogs, restore ROI discipline, and close the digital gap.

  • Reallocate $18.6B from Dogs into Stars & Expand-rated growth.
  • Install ROI-adjusted-for-risk stage-gates to cut the 7% value-destructive tail.
  • Fund an enterprise AI/digital uplift — the single largest cross-cutting margin lever.
  • Govern with the 12-KPI cadence and named C-suite owners (§18).
The ask: a 3-year mandate and ring-fenced transformation budget, targeting blended ROI +15pp and Star revenue share ≥40% by Year 3.
All metrics computed from pharma_consultant_strategy_builder_demo_30000.xlsx (30,000 projects). Frameworks (BCG, GE-McKinsey, Ansoff) applied to the dataset as provided; scenario projections are directional envelopes with stated assumptions, not guidance.